Efficacy and Safety of Eculizumab in Asian Patients WithAquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder: Subgroup Analysis From the Phase 3 PREVENT Study

被引：0
|
作者：
Kim, H. J. [1 ]
Berthele, A. [2 ]
Fujihara, K. [3 ,4 ,5 ]
Levy, M. [6 ,7 ,8 ]
Palace, J. [9 ]
Nakashima, I. [3 ,10 ]
Totolyan, N. [11 ]
Viswanathan, S. [12 ]
Wang, K-C. [13 ,14 ]
Pace, A. [15 ]
Armstrong, R. [15 ]
Miller, L. [15 ]
Yountz, M. [15 ]
Wingerchuk, D. M. [16 ]
Pittock, S. J. [17 ]
机构：
[1] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea
[2] Tech Univ Munich, Klinikum Rechts Isar, Munich, Germany
[3] Tohoku Univ, Sendai, Miyagi, Japan
[4] Fukushima Med Univ, Fukushima, Japan
[5] Southern TOHOKU Res Inst Neurosci STRINS, Koriyama, Fukushima, Japan
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
[8] Harvard Med Sch, Boston, MA 02115 USA
[9] John Radcliffe Hosp, Oxford, England
[10] Tohoku Med & Pharmaceut Univ, Sendai, Miyagi, Japan
[11] First Pavlov State Med Univ St Petersburg, St Petersburg, Russia
[12] Kuala Lumpur Hosp, Kuala Lumpur, Malaysia
[13] Cheng Hsin Gen Hosp, Taipei, Taiwan
[14] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan
[15] Alex Pharmaceut, Boston, MA USA
[16] Mayo Clin, Scottsdale, AZ USA
[17] Mayo Clin, Rochester, MN USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O-4
引用
收藏
页码：NP38 / NP39
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study
    Fujihara, Kazuo
    Kim, Ho Jin
    Saida, Takahiko
    Misu, Tatsuro
    Nagano, Yoshito
    Totsuka, Naoko
    Iizuka, Masato
    Kido, Shinsuke
    Terata, Ryuuji
    Okumura, Kyoko
    Hirota, Shinya
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [22] Efficacy and safety of eculizumab in aquaporin-4-antibody-positive neuromyelitis optica spectrum disorder: A phase 3, randomized, double-blind, placebo-controlled, multicenter trial (PREVENT)
    Pittock, Sean J.
    Berthele, Achim
    Fujihara, Kazuo
    Kim, Ho Jin
    Levy, Michael
    Palace, Jacqueline
    Nakashima, Ichiro
    Terzi, Murat
    Totolyan, Natalia
    Viswanathan, Shanthi
    Wang, Kai-Chen
    Armstrong, Roisin
    Fujita, Kenji
    Pace, Amy
    Wingerchuk, Dean M.
    NEUROLOGY, 2019, 93 (05) : E534 - E535
  • [23] Re: You et al.: Evidence of Muller glial dysfunction in patients with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder
    Mahroo, Omar A.
    OPHTHALMOLOGY, 2019, 126 (08) : E63 - E64
  • [24] Benefit of eculizumab for a broad range of patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from prevent
    Fujihara, K.
    Berthele, A.
    Kim, H. J.
    Levy, M.
    Nakashima, I.
    Oreja-Guevara, C.
    Palace, J.
    Pittock, S.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K. -C.
    Pace, A.
    Yountz, M.
    Miller, L.
    Tanvir, I.
    Armstrong, R.
    Wingerchuk, D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 447 - 448
  • [25] Efficacy and safety of satralizumab from two phase 3 trials in neuromyelitis optica spectrum disorder
    Haskova, Zdenka
    Frishberg, Benjamin
    de Seze, Jerome
    Weinshenker, Brian
    Terada, Yusuke
    Kawata, Yuichi
    Gianella-Borradori, Athos
    von Budingen, Christian
    Klingelschmitt, Gaelle
    Traboulsee, Anthony
    Yamamura, Takashi
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [26] Impact of eculizumab on reported quality of life in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the PREVENT study
    Berthele, A.
    Pittock, S. J.
    Fujihara, K.
    Kim, H. J.
    Levy, M.
    Palace, J.
    Nakashima, I.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K. -C.
    Pace, A.
    Fujita, K. P.
    Yountz, M.
    Armstrong, R.
    Wingerchuk, D. M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 294 - 295
  • [27] A Phase 3 Efficacy and Safety Study of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder: Study Design and Methodology
    Pittock, Sean
    Allen, Kerstin
    Mashhoon, Yasmin
    Yountz, Marcus
    NEUROLOGY, 2022, 99 (23) : S4 - S5
  • [28] A Phase 3 Efficacy and Safety Study of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder: Study Design and Methodology
    Pittock, S. J.
    Allen, K.
    Mashhoon, Y.
    Yountz, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 142 - 143
  • [29] Switch from eculizumab to satralizumab in aquaporin 4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder: a case series report
    Abboud, Hesham
    Subei, Adnan
    Sengul, Buse
    Shin, Robert K.
    Goulette, Paige
    Walch, Rosemarie
    Cote, Jeanie
    Pace, Robert
    Obeidat, Ahmed Z.
    Ferayorni, Lisa
    Gholizadeh, Shervin
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [30] A Comparison of Pediatric- and Adult-Onset Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder: A Review of Clinical and Radiographic Characteristics
    Tarhan, Bedirhan
    Rempe, Torge
    Rahman, Sydur
    Rodriguez, Elsa
    Sladky, John
    Tuna, Ibrahim Sacit
    Rees, John
    JOURNAL OF CHILD NEUROLOGY, 2022, 37 (8-9) : 727 - 737
12345